Efficacy of GPE− strain live attenuated vaccine and CP7_E2alf strain recombinant live vaccine (marker vaccine) against Japanese epidemic classical swine fever virus isolated in 2019 and DIVA discrimination ability of the marker vaccine

This is the authors' abstract. We don't add key points for this paper.

Classical swine fever (CSF) re-emerged in Japan in 2018, with the epidemic virus identified as genotype 2.1, which is moderately virulent and more difficult to detect and control than the highly virulent strain. Domestic pigs were administered with GPE − strain live attenuated vaccine (GPE − vaccine) for outbreak management. CP7_E2alf strain recombinant live vaccine (marker vaccine), approved for differentiation of infected from vaccinated animals (DIVA), was considered optional for obtaining CSF-free country certification issued by the World Organization for Animal Health. This study aimed to assess the efficacy of both vaccines in pigs through experimental challenge tests and evaluate the DIVA ability of the marker vaccine using two enzyme-linked immunosorbent assay (ELISA) antibody detection kits. Results showed that both GPE − and marker vaccines were effective against the Japanese epidemic strain; however, the ability of the ELISA antibody detection kits to discriminate the marker vaccine was limited. Therefore, to achieve CSF-free certification using vaccines with DIVA functionality, alternative detection methods and enhancement of the sensitivity and specificity of ELISA kits are needed. • The classical swine fever virus identified in Japan was moderately virulent. • GPE − strain vaccine began to show efficacy from 3 days post vaccination (dpv). • CP7_E2alf strain (marker) vaccine was robustly effective at 28 dpv. • DIVA function of the marker vaccine was not specific and sensitive.

Experimental efficacy supports CSF vaccine options including DIVA; leaves open field validation in ongoing Japanese outbreaks.